Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention. METHODS: To compare prasugrel, a new thienopyridine, with clopidogrel, we randomly assigned 13,608 patients with moderate-to-high-risk acute coronary syndromes with scheduled percutaneous coronary intervention to receive prasugrel (a 60-mg loading dose and a 10-mg daily maintenance dose) or clopidogrel (a 300-mg loading dose and a 75-mg daily maintenance dose), for 6 to 15 months. The primary efficacy end point was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The key safety end point was major bleeding. RESULTS: The primary efficacy end point occurred in 12.1% of patients receiving clopidogrel and 9.9% of patients receiving prasugrel (hazard ratio for prasugrel vs. clopidogrel, 0.81; 95% confidence interval [CI], 0.73 to 0.90; P<0.001). We also found significant reductions in the prasugrel group in the rates of myocardial infarction (9.7% for clopidogrel vs. 7.4% for prasugrel; P<0.001), urgent target-vessel revascularization (3.7% vs. 2.5%; P<0.001), and stent thrombosis (2.4% vs. 1.1%; P<0.001). Major bleeding was observed in 2.4% of patients receiving prasugrel and in 1.8% of patients receiving clopidogrel (hazard ratio, 1.32; 95% CI, 1.03 to 1.68; P=0.03). Also greater in the prasugrel group was the rate of life-threatening bleeding (1.4% vs. 0.9%; P=0.01), including nonfatal bleeding (1.1% vs. 0.9%; hazard ratio, 1.25; P=0.23) and fatal bleeding (0.4% vs. 0.1%; P=0.002). CONCLUSIONS: In patients with acute coronary syndromes with scheduled percutaneous coronary intervention, prasugrel therapy was associated with significantly reduced rates of ischemic events, including stent thrombosis, but with an increased risk of major bleeding, including fatal bleeding. Overall mortality did not differ significantly between treatment groups. (ClinicalTrials.gov number, NCT00097591 [ClinicalTrials.gov].)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In patients with ACS undergoing PCI, 12 months' DAPT with low-dose ASA and prasugrel or ticagrelor was superior to DAPT with clopidogrel in the diabetes sub-group of the respective RCTs, with a benefit-risk profile similar to the overall trial populations (Supplementary data online, Tables S12-13).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [310]
In the citing paper
“With prasugrel, the primary efficacy endpoint occurred in 9.9% of patients as compared with 12.1% receiving clopidogrel (HR 0.81, 95% CI 0.73-0.90;P , 0.001).The risk of major bleeding was increased with prasugrel.501”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [501]
In the citing paper
“With ticagrelor given for 12 months the composite endpoint of death from vascular causes, myocardial infarction, or stroke occurred in 9.8% as compared with 11.7% of those receiving clopidogrel (HR 0.84, 95% CI 0.77-0.92;P , 0.001).No significant difference in rate of major bleeding was found.501 -503”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [501]
In the citing paper
“In patients with ACS for whom an early invasive strategy is planned, dual antiplatelet therapy with a P2Y12 inhibitor (ticagrelor or prasugrel) added to aspirin was superior to clopidogrel and aspirin.”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [501]
Citations
Cites
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Antman, E. M., Cohen, M., Bernink, P. J. L. M., McCabe, C. H., Horacek, T., Papuchis, G., Mautner, B., Corbalan, R., Radley, D., & Braunwald, E. (2000) · JAMA · doi:10.1001/jama.284.7.835 · Cited by 3,242
Self-citationSteinhubl, S. R., Berger, P. B., Mann III, J. T., Fry, E. T. A., DeLago, A., Wilmer, C., Topol, E. J., & for the CREDO Investigators (2002) · JAMA · doi:10.1001/jama.288.19.2411 · Cited by 3,078
Diener, H.-C., Bogousslavsky, J., Brass, L. M., Cimminiello, C., Csiba, L., Kaste, M., Leys, D., Matias-Guiu, J., & Rupprecht, H.-J. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16721-4 · Cited by 2,275
WRITING COMMITTEE MEMBERS, Smith, S. C., Feldman, T. E., Hirshfeld, J. W., Jacobs, A. K., Kern, M. J., King, S. B., Morrison, D. A., O’Neill, W. W., Schaff, H. V., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.170815 · Cited by 2,218
Self-citationSabatine, M. S., Cannon, C. P., Gibson, C. M., López-Sendón, J. L., Montalescot, G., Theroux, P., Claeys, M. J., Cools, F., Hill, K. A., Skene, A. M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050522 · Cited by 1,924
Self-citation(2005) · The Lancet · doi:10.1016/s0140-6736(05)67660-x · Cited by 1,858
Guidelines for Percutaneous Coronary Interventions
Silber, S., Albertsson, P., Avilés, F. F., Camici, P. G., Colombo, A., Hamm, C., Jørgensen, E., Marco, J., Nordrehaug, J.-E., Ruzyllo, W., et al. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi138 · Cited by 1,609
Stent Thrombosis in Randomized Clinical Trials of Drug-Eluting Stents
Mauri, L., Hsieh, W.-H., Massaro, J. M., Ho, K. K. L., D'Agostino, R., & Cutlip, D. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067731 · Cited by 1,441
(1998) · New England Journal of Medicine · doi:10.1056/nejm199808133390704 · Cited by 1,432
Matetzky, S., Shenkman, B., Guetta, V., Shechter, M., Beinart, R., Goldenberg, I., Novikov, I., Pres, H., Savion, N., Varon, D., et al. (2004) · Circulation · doi:10.1161/01.cir.0000130846.46168.03 · Cited by 1,354
(1998) · New England Journal of Medicine · doi:10.1056/nejm199805213382102 · Cited by 1,321
Wiviott, S. D., Trenk, D., Frelinger, A. L., O’Donoghue, M., Neumann, F.-J., Michelson, A. D., Angiolillo, D. J., Hod, H., Montalescot, G., Miller, D. L., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.740324 · Cited by 881
Self-citationFox, K. A. A., Mehta, S. R., Peters, R., Zhao, F., Lakkis, N., Gersh, B. J., & Yusuf, S. (2004) · Circulation · doi:10.1161/01.cir.0000140675.85342.1b · Cited by 835
Variability in platelet responsiveness to clopidogrel among 544 individuals
Serebruany, V. L., Steinhubl, S. R., Berger, P. B., Malinin, A. I., Bhatt, D. L., & Topol, E. J. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.09.067 · Cited by 777
Alexander, K. P. (2005) · JAMA · doi:10.1001/jama.294.24.3108 · Cited by 677
Impact of Platelet Reactivity After Clopidogrel Administration on Drug-Eluting Stent Thrombosis
Buonamici, P., Marcucci, R., Migliorini, A., Gensini, G. F., Santini, A., Paniccia, R., Moschi, G., Gori, A. M., Abbate, R., & Antoniucci, D. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.01.094 · Cited by 656
Patti, G., Colonna, G., Pasceri, V., Pepe, L. L., Montinaro, A., & Di Sciascio, G. (2005) · Circulation · doi:10.1161/01.cir.0000161383.06692.d4 · Cited by 652
von Beckerath, N., Taubert, D., Pogatsa-Murray, G., Schömig, E., Kastrati, A., & Schömig, A. (2005) · Circulation · doi:10.1161/circulationaha.105.559088 · Cited by 623
Hochholzer, W., Trenk, D., Bestehorn, H.-P., Fischer, B., Valina, C. M., Ferenc, M., Gick, M., Caputo, A., Büttner, H. J., & Neumann, F.-J. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.06.065 · Cited by 589
Self-citationBrandt, J. T., Payne, C. D., Wiviott, S. D., Weerakkody, G., Farid, N. A., Small, D. S., Jakubowski, J. A., Naganuma, H., & Winters, K. J. (2007) · American Heart Journal · doi:10.1016/j.ahj.2006.10.010 · Cited by 571
Self-citationJernberg, T., Payne, C. D., Winters, K. J., Darstein, C., Brandt, J. T., Jakubowski, J. A., Naganuma, H., Siegbahn, A., & Wallentin, L. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi877 · Cited by 538
Clopidogrel Effect on Platelet REactivity in Patients With Stent Thrombosis
Gurbel, P. A., Bliden, K. P., Samara, W., Yoho, J. A., Hayes, K., Fissha, M. Z., & Tantry, U. S. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.07.056 · Cited by 536
Montalescot, G., Sideris, G., Meuleman, C., Bal-dit-Sollier, C., Lellouche, N., Steg, P. G., Slama, M., Milleron, O., Collet, J.-P., Henry, P., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.04.090 · Cited by 527
Self-citationAspirin Dose for the Prevention of Cardiovascular Disease: A Systematic Review
Campbell, C. L., Smyth, S., Montalescot, G., & Steinhubl, S. R. (2007) · JAMA · doi:10.1001/jama.297.18.2018 · Cited by 444
Self-citationACC/AHA/SCAI Practice Guidelines, February 21, 2006
(2006) · Circulation · doi:10.1161/circulationaha.106.173220 · Cited by 422
Wiviott, S. D., Antman, E. M., Winters, K. J., Weerakkody, G., Murphy, S. A., Behounek, B. D., Carney, R. J., Lazzam, C., McKay, R. G., McCabe, C. H., et al. (2005) · Circulation · doi:10.1161/circulationaha.104.502815 · Cited by 381
Self-citationWiviott, S. D., Antman, E. M., Gibson, C. M., Montalescot, G., Riesmeyer, J., Weerakkody, G., Winters, K. J., Warmke, J. W., McCabe, C. H., & Braunwald, E. (2006) · American Heart Journal · doi:10.1016/j.ahj.2006.04.012 · Cited by 324
Self-citationNiitsu, Y., Jakubowski, J. A., Sugidachi, A., & Asai, F. (2005) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-2005-869524 · Cited by 236
ESC guidelines for percutaneous coronary interventions: reply
Silber, S. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi564 · Cited by 213
[Guidelines for percutaneous coronary interventions].
Silber, S., Albertsson, P., Fernández‐Avilés, F., Camici, P. G., Colombo, A., Hamm, C. W., Jørgensen, E. O., Marco, J., Nordrehaug, J.-E., Rużyłło, W., et al. (2005) · PubMed · Cited by 201
Durability of platelet inhibition by clopidogrel
Gurbel, P. A., & Bliden, K. P. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00163-2 · Cited by 131
Mehta, S. R., & Yusuf, S. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02831-0 · Cited by 97
Stroke in Patients With Acute Coronary Syndromes
Mahaffey, K. W., Harrington, R. A., Simoons, M. L., Granger, C. B., Graffagnino, C., Alberts, M. J., Laskowitz, D. T., Miller, J. M., Sloan, M. A., Berdan, L. G., et al. (1999) · Circulation · doi:10.1161/01.cir.99.18.2371 · Cited by 82
Significance of occult gastrointestinal bleeding during anticoagulation therapy
Jaffin, B. W., Bliss, C. M., & LaMont, J. T. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90697-8 · Cited by 62
Wolfram, R. M., Torguson, R., Hassani, S., Xue, Z., Gevorkian, N., Pichard, A. D., Satler, L. F., Kent, K. M., & Waksman, R. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.10.064 · Cited by 40
Learning from the Recently Completed Oral Glycoprotein IIb/IIIa Receptor Antagonist Trials
Cannon, C. P. (2000) · Clinical Cardiology · doi:10.1002/clc.4960231105 · Cited by 19
WARFARIN-INDUCED RECTAL BLEEDING AS CLUE TO COLON CANCER
Carey, R. W. (1984) · The Lancet · doi:10.1016/s0140-6736(84)92864-2 · Cited by 13
Research works printed but not linked: 1
- Varenhorst C, 2007, Eur Heart J, 28, 189
Cited by
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Self-citationEuropean Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Roffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citation2018 ESC/EACTS guidelines on myocardial revascularization
Neumann, F.-J., Sousa-Uva, M., Ahlsson, A., Alfonso, F., Banning, A. P., Benedetto, U., Byrne, R. A., Collet, J.-P., Falk, V., Head, S. J., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy394 · Cited by 7,167
Self-citation2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes
Knuuti, J., Wijns, W., Saraste, A., Capodanno, D., Barbato, E., Funck-Brentano, C., Prescott, E., Storey, R. F., Deaton, C., Cuisset, T., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz425 · Cited by 7,166
Self-citation
Metadata
- Authors
- Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., Riesmeyer, J., Weerakkody, G., Gibson, C. M., & Antman, E. M.
- Affiliations
- Brigham and Women's Hospital (US)
- Inserm (FR)
- Bikur Cholim Hospital (IL)
- Universitäts-Herzzentrum Freiburg-Bad Krozingen (DE)
- Ospedale di Parma (IT)
- Eli Lilly (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-15
- Volume
- 357
- Issue
- 20
- Pages
- 2001-2015
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2169387542
- Cited by
- 6,790
- References
- 40
- Citations by year
- 2026: 162 · 2025: 202 · 2024: 187 · 2023: 265 · 2022: 309 · 2021: 326 · 2020: 339 · 2019: 361 · 2018: 389 · 2017: 418 · 2016: 419 · 2015: 465 · 2014: 448 · 2013: 502 · 2012: 507
- FWCI
- 238.04
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- prasugrel, clopidogrel, acute coronary syndrome, percutaneous coronary intervention, dual antiplatelet therapy, thienopyridines, major bleeding, stent thrombosis, myocardial infarction, target vessel revascularization, cardiovascular mortality, bleeding risk stratification, bleeding risk score
- MeSH terms
- Prasugrel Hydrochloride, Clopidogrel, Aged, Aspirin, Double-Blind Method, Drug Therapy, Combination, Female, Hemorrhage, Humans, Male, Middle Aged, Myocardial Infarction, Piperazines, Platelet Aggregation Inhibitors, Prodrugs, Thiophenes, Thrombosis, Ticlopidine, Angioplasty, Balloon, Coronary, Stroke, Kaplan-Meier Estimate, Acute Coronary Syndrome, Purinergic P2 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.